Ceritinib was granted Breakthrough Therapy designation by the FDA, along with a priority review for first-line therapy in this patient population.
Ceritinib ໄດ້ຮັບອະນຸຍາດອອກແບບ Breakthrough Therapy ໂດຍ FDA, ພ້ອມກັບການທົບທວນບູລິມະສິດ ສໍາ ລັບການປິ່ນປົວດ້ວຍເສັ້ນ ທໍາ ອິດໃນປະຊາກອນຄົນເຈັບນີ້.